GSK AWP settlement
Executive Summary
GlaxoSmithKline settles average wholesale price class action litigation for $70 mil., the company announces Aug. 10. Plaintiffs alleged that GSK inflated certain AWPs - primarily for antiemetics Zofran and Kytril. The settlement, which covers all claims filed in Boston federal court, resolves most of the AWP litigation pending against GSK, company says. GSK reached civil settlements with six state attorneys general as part of a September settlement with the Department of Justice over Zofran and Kytril pricing (1"The Pink Sheet" Sept. 26, 2005, p. 6). Reportedly, there are more than a dozen remaining defendants involved in the AWP litigation, including AstraZeneca and Bristol-Myers Squibb...
You may also be interested in...
GSK’s AWP Pricing Settlement Includes Expanded Training Of Sales Reps
GlaxoSmithKline's $150 mil. settlement with the Department of Justice requires the company to expand its compliance training for its sales reps
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.